Christopher Missling [Audio gap] the quest for disease-confined therapies for neurodegenerative disorders. Separately, the independent Data Monitoring Safety Board, DSMB, also like the ongoing clinical trial program, including the late-stage AVATAR RS-002, EXCELLENCE RS-003, and the US Rett syndrome extension study, RS-EP-001 of Anavex 2-73 has also completed its recent pre-planned review of the respective interim safety data for these three separate clinical studies. Upon review of the interim safety data, the DSMB made the following recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications. This is very good news and indicates we're on the right path with all these studies. As a reminder, our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS. Anavex is continuing to pioneer the approach of big data, including Anavex in clinical trials to leverage the level of phenotypic and genotypic precision medicine analysis of whole genome sequencing and gene expression data in drug development. And in particular, the potential to identify patient's genetic variance and gene expression changes that may predict increased chance of success for Rett syndrome, Parkinson's disease and Alzheimer's disease treatments.